Date: 04th September,2026

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051, Maharashtra, India.

Sub: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) (LODR) Regulations, 2015
Ref: NSE Symbol: Madhavbaug // ISIN: INE0JR301013

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of **Vaidya Sane Ayurved Laboratories Limited**, at its Meeting held today i.e. **Friday, 04 September, 2026**, has, inter alia, considered and approved the following:

1. Finalized the dates of the Book Closure from Wednesday 23rd September 2026 to Wednesday, 30th September 2026 (both days inclusive) for the forthcoming 27th Annual General Meeting to be held on Wednesday, 30th September 2026;

2. Approved the Board report along with all annexures.

3. Approved the notice convening 27th Annual General Meeting.

4. Decided to convene Annual General Meeting of the Company to be convened on Wednesday, 30th September 2026 at 01.00 PM., through Video Conferencing/ Other Audio Visual Means (OAVM) in compliance with the applicable provisions of the Companies Act, 2013 read with MCA and SEBI Circulars.

5. Mr. Deep Shukla, (Membership No. FCS 5652), of M/s. Deep Shukla & Associates, Practicing Company Secretary, is appointed as the Scrutinizer for conducting "Remote E voting" and "E- voting during the AGM" process for ensuing Annual General Meeting.

6. Cut-off date for determining the eligibility to vote by electronic means for the purpose of Annual General Meeting shall be Wednesday, 23rd September 2026.

Registered Office Address:
Fl. 5 1047, Shriram Bhawan, Shukrawar Peth, Pune 411002,
Maharashtra, India.
CIN: L73100PN1999PLC013509

Corporate office Address:
1702 to 1706, 17th Floor, Mahavir Business Park, Opp. Eternity Mall,
Teen Haath Naka, LBS Road, Thane (W) - 400604. Maharashtra, India.
Tel: 022-41235315/16
www.madhavbaug.org

7. The Board considered the recommendation of the Audit Committee and recommended the re-appointment of M/s. A.A. Mohare & Co., Chartered Accountants (Firm Registration No. 114152W), as Statutory Auditors of the Company for a further term of five (5) years, from the conclusion of the ensuing AGM until the conclusion of the AGM to be held in the year 2031, subject to the approval of the Members.

8. The Board considered the recommendation of the Nomination and Remuneration Committee and **recommended the re-appointment of Mr. Ratnakar Venkappa Rai (DIN: 00126309) as Non-Executive Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years**, from **30th September 2026 to 30th September 2031**, subject to the approval of the Members at the ensuing Annual General Meeting.

9. The Board considered the recommendation of the Nomination and Remuneration Committee and **recommended the re-appointment of Mr. Mahesh Kshirsagar (DIN: 07612577) as Non-Executive Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years**, from **30th September 2026 to 30th September 2031**, subject to the approval of the Members at the ensuing Annual General Meeting.

10. The Board considered the recommendation of the Nomination and Remuneration Committee and **recommended the re-appointment of Mr. Sushrut Dambal (DIN: 06795550) as Non-Executive Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years**, from **30th September 2026 to 30th September 2031**, subject to the approval of the Members at the ensuing Annual General Meeting.

11. The Board considered the recommendation of the Nomination and Remuneration Committee and **recommended the re-appointment of Dr. Rohit Madhav Sane (DIN: 02808693) as Managing Director of the Company for a further term of five (5) consecutive years**, from **30th September 2026 to 30th September 2031**, along with the proposed terms and remuneration, subject to the approval of the Members at the ensuing Annual General Meeting.

12. The Board considered the recommendation of the Nomination and Remuneration Committee and **recommended the re-appointment of Ms. Vidyut Ghag (DIN: 09299252) as Whole-Time Director of the Company for a further term of five (5) consecutive years**, from **30th September 2026 to 30th September 2031**, along with the proposed terms and remuneration, subject to the approval of the Members at the ensuing Annual General Meeting.

13. The Board considered the recommendation of the Nomination and Remuneration Committee and **recommended the increase in the overall limit of maximum remuneration payable to Dr. Rohit Madhav Sane (DIN: 00679851), Managing Director, for the period from 30th September 2026 to 30th September 2031**, as set out in the Explanatory Statement, including payment of minimum remuneration in the event of absence or inadequacy of profits, subject to the approval of the Members by way of Special Resolution.

14. Based on the recommendation of the Nomination and Remuneration Committee, Board of Directors has inter alia considered, and approved the Introduction of **'VAIDYA SANE AYURVED LABORATORIES LIMITED - EMPLOYEE STOCK OPTION PLAN 2026' ("VSALL - ESOP 2026")** and related matters which will be subject to approval by the shareholders'.

    The details of the same as required pursuant to Regulation 30 of the Listing Regulations read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is annexed as "Annexure A" to this letter.

The Meeting of the Board of Directors commenced at **12:00 P.M. (IST)** and concluded at **4 P.M. (IST).**

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Vaidya Sane Ayurved Laboratories Limited

Rohit Madhav Sane

Digitally signed by Rohit Madhav Sane
Date: 2026.09.04 16:04:33 +05'30'

Dr. Rohit Sane
Managing Director and Chief Executive Officer
DIN: 00679851

<u>**Annexure A**</u>

(Subject to approval of Shareholders)

Particulars	**'VAIDYA SANE AYURVED LABORATORIES LIMITED - EMPLOYEE STOCK OPTION PLAN 2026' ("VSALL - ESOP 2026")**
Brief details of options granted	**'VAIDYA SANE AYURVED LABORATORIES LIMITED - EMPLOYEE STOCK OPTION PLAN 2026' ("VSALL - ESOP 2026")** has been formulated by the Company and to be implemented by its Board of Directors/Compensation Committee/Nomination & Remuneration Committee in terms of provisions of Companies Act, 2013 and rules made thereunder, Regulation 19 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 issued by Securities and Exchange Board of India (**the "SEBI"**) and other applicable laws. The **VSALL - ESOP 2026** has been approved by the Board of Directors at their meeting held on 04th September, 2026, subject to the approval of the members.
Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
Total number of shares covered by these options	3,00,000 (Three Lakh)
Pricing formula;	The exercise price shall be as may be decided by the Board/ Committee as is allowed under the Act / SEBI (SBEB and Sweat Equity) Regulations, which in any case will not be lower than the face value of the equity shares of the Company on the date of such grant. Further the exercise price can be different for different set of Employees for Options granted on same / different dates. Payment of the Exercise Price shall be made by a crossed cheque or a demand draft drawn in favour of the Company, or by any other payment methods prevalent in RBI recognized banking channels or in such other manner and subject to such procedures as the Board / Committee may decide. No amount shall be payable by the option grantee at the time of grant. Notwithstanding anything contained hereinabove, amount paid/payable, if any, by the employee at the time of the grant,

	vesting or exercise of the options will be forfeited if the employee does not exercise the same within the exercise period.
Options vested	Nil
Time within which option may be exercised	The exercise period shall not be more than 5 (Five) years from the date of respective vesting of Options.
Options exercised;	Nil
Money realized by exercise of options	Not Applicable
The total number of shares arising as a result of exercise of option	3,00,000 (Three Lakh)
Options lapsed	Not Applicable
Variation of terms of options	Not Applicable
Brief details of significant terms	**Eligibility:** Employee/s as may be determined by the Board/ Committee out of the following: - (i) an employee as designated by the Company, who is exclusively working in India or outside India; or (ii) a Director of the Company, whether a whole time Director or not, including a non-executive Director who is not a Promoter or member of the Promoter Group, but excluding an independent Director; or (iii) an employee as defined in sub-clauses (i) or (ii), of a Group Company including Subsidiary or its Associate Company, in India or outside India, or of a Holding Company of the Company, but does not include— (a) an Employee who is a Promoter or a person belonging to the Promoter group; or (b) a Director who, either himself or through his relative or through anybody corporate, directly or indirectly, holds more than ten per cent of the outstanding equity Shares of the Company; The appraisal process for determining the eligibility of the Employees will be specified by the Board/ Committee and will be based on criteria such as the grade of Employee, length of service, performance record, merit of the Employee, future potential contribution by the Employee and/or by any such criteria that may be determined by the Board/ Committee from time to time. **Vesting:** Vesting is linked to continued association with the Company and is subject to performance /other parameters as the Board/ Committee may specify additionally. The options

	would vest not earlier than **1 (One)** year and not later than **8 (Eight)** years from the date of individual grant as decided by the Board/ Committee. The vesting may occur in one or more tranches, subject to the terms and conditions of vesting, as stipulated in **VSALL - ESOP 2026**. **Exercise Period:** Exercise period shall not be more than **5 (five) years** from the date of respective vesting of Options and same can be exercised in tranches within the exercise period. **Administration:** The VSALL - ESOP 2026 shall be administered by the Board or by the Committee as may be authorized by the Board. All questions of interpretation of the VSALL - ESOP 2026 shall be determined by the Board/ Committee and such determination shall be final and binding upon all persons having an interest in the VSALL - ESOP 2026, in compliance with Applicable Laws.
Subsequent changes or cancellation or exercise of such options	Not Applicable
Diluted earnings per share pursuant to issue of equity shares on exercise of options	The diluted earnings per share shall be determined on exercise of options.